BEYFORTUS® reduced hospital and doctor visits for RSV disease in babies by 87%, according to largest US real-world study

Provided By PR Newswire

Last update: Jul 22, 2025

MORRISTOWN, N.J., July 22, 2025 /PRNewswire/ -- The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies against RSV disease. The full results from the "Effectiveness of nirsevimab against RSV and RSV-related events in infants" study have been published in PEDIATRICS^®, an official journal of the American Academy of Pediatrics.